SubHero Banner

Keytruda® (pembrolizumab) – Expanded indication

October 15, 2020 - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.

Download PDF